Pédiatrie Tumeurs solides
D419EC00001
Phase I/II, open-label, multicentre study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in paediatric patients with advanced solid tumours, haematological malignancies including lymphoma and acute leukaemias
Paris
FRANCOIS DOZ